Who Exports Ipratropium from India — 173 Suppliers Behind a $57.1M Market
India's ipratropium export market is supplied by 173 active exporters who collectively shipped $57.1M across 2,297 shipments. CIPLA LIMITED leads with a 84.7% market share, followed by AHLCON PARENTERALS (INDIA) LIMITED and SUN PHARMACEUTICAL INDUSTRIES LIMITED. The top 5 suppliers together control 95.0% of total export value, reflecting a concentrated market structure.
Top Ipratropium Exporters from India — Ranked by Export Value
CIPLA LIMITED is the leading ipratropium exporter from India, holding a 84.7% share of the $57.1M market across 2,297 shipments from 173 exporters. The top 5 suppliers — CIPLA LIMITED, AHLCON PARENTERALS (INDIA) LIMITED, SUN PHARMACEUTICAL INDUSTRIES LIMITED, ALTHEA PHARMA PRIVATE LIMITED, AHLCON PARENTERALS INDIA LIMITED — collectively control 95.0% of total export value, indicating a highly concentrated market. Individual shares are: CIPLA LIMITED (84.7%), AHLCON PARENTERALS (INDIA) LIMITED (4.4%), SUN PHARMACEUTICAL INDUSTRIES LIMITED (4.0%), ALTHEA PHARMA PRIVATE LIMITED (1.2%), AHLCON PARENTERALS INDIA LIMITED (0.8%).
Top Ipratropium Exporters from India
Ranked by export value · 173 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | CIPLA LIMITED DUOLIN RESPULES 2.5ML RESPULES) [17280X12X5'S]DUOLIN RESPULES 2.5ML RESPULES) [17136X12X5'S]DUOLIN RESPULES 2.5ML RESPULES) [15600X12X5'S] | $48.3M | 19 | 84.7% |
| 2 | AHLCON PARENTERALS (INDIA) LIMITED DUOLIN RESPULES 2.5ML RESPULES) [17280X12X5'S]DUOLIN RESPULES 2.5ML RESPULES) [17136X12X5'S]DUOLIN RESPULES 2.5ML RESPULES) [15600X12X5'S] | $2.5M | 3 | 4.4% |
| 3 | SUN PHARMACEUTICAL INDUSTRIES LIMITED IPRATROPIUM BROMIDE AND ALBUTEROL SULFAT | $2.3M | 1 | 4.0% |
| 4 | ALTHEA PHARMA PRIVATE LIMITED SALBUTAMOL & IPRATROPIUM BROMIDE RESPIRASALBUTAMOL & IPRATROPIUM BROMIDE RESPIRATOR SOLUTION 2.5MLSALBUTAMOL& IPRATROPIUM BROMIDE RESPIRAT | $685.5K | 1 | 1.2% |
| 5 | AHLCON PARENTERALS INDIA LIMITED DUOLIN RESPULES 2.5ML RESPULES) [17280X12X5'S]DUOLIN RESPULES 2.5ML RESPULES) [17136X12X5'S]DUOLIN RESPULES 2.5ML RESPULES) [15600X12X5'S] | $431.7K | 1 | 0.8% |
| 6 | MGRM MEDICARE PRIVATE LIMITED SALBUTAMOL & IPRATROPIUM BROMIDE RESPIRASALBUTAMOL & IPRATROPIUM BROMIDE RESPIRATOR SOLUTION 2.5MLSALBUTAMOL& IPRATROPIUM BROMIDE RESPIRAT | $328.7K | 1 | 0.6% |
| 7 | RUBICON RESEARCH LIMITED IPRATROPIUM BROMIDE AND ALBUTEROL SULFAT | $292.3K | 2 | 0.5% |
| 8 | SUN PHARMACEUTICAL INDUSTRIES LTD IPRATROPIUM BROMIDE AND ALBUTEROL SULFAT | $260.6K | 1 | 0.5% |
| 9 | SOLITAIRE PHARMACIA PRIVATE LIMITED H.L.MEDICINE AS PER INV.BREATHON-S200 METERED DOSEH.L.MEDICINE AS PER INV.BREATHON 200 METERED DOSEINHALLERIPRAMED | $249.1K | 1 | 0.4% |
| 10 | LEGENCY REMEDIES PRIVATE LIMITED SALBUTAMOL & IPRATROPIUM BROMIDE RESPIRASALBUTAMOL & IPRATROPIUM BROMIDE RESPIRATOR SOLUTION 2.5MLSALBUTAMOL& IPRATROPIUM BROMIDE RESPIRAT | $221.4K | 3 | 0.4% |
| 11 | AHLCON PARENTERALS INDIA LTD DUOLIN RESPULES 2.5ML RESPULES) [17280X12X5'S]DUOLIN RESPULES 2.5ML RESPULES) [17136X12X5'S]DUOLIN RESPULES 2.5ML RESPULES) [15600X12X5'S] | $165.9K | 2 | 0.3% |
| 12 | MIDAS CARE PHARMACEUTICALS PVT LTD SALBUTAMOL & IPRATROPIUM BROMIDE RESPIRASALBUTAMOL & IPRATROPIUM BROMIDE RESPIRATOR SOLUTION 2.5MLSALBUTAMOL& IPRATROPIUM BROMIDE RESPIRAT | $161.6K | 1 | 0.3% |
| 13 | AXA PARENTERALS LIMITED H.L.MEDICINE AS PER INV.BREATHON-S200 METERED DOSEH.L.MEDICINE AS PER INV.BREATHON 200 METERED DOSEINHALLERIPRAMED | $141.7K | 3 | 0.2% |
| 14 | NOBLE WELLNESS PRIVATE LIMITED | $84.6K | 1 | 0.1% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Ipratropium exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| CIPLA LIMITED | Approved | Yes | Yes | Multiple | Cipla Limited holds FDA approval, WHO-GMP, and EU GMP certifications. |
| SUN PHARMACEUTICAL INDUSTRIES LIMITED | Approved | Yes | Yes | Multiple | Sun Pharmaceutical Industries Limited holds FDA approval, WHO-GMP, and EU GMP ce |
| AHLCON PARENTERALS (INDIA) LIMITED | Not Listed | Yes | No | Not Applicable | Ahlcon Parenterals (India) Limited holds WHO-GMP certification. |
| AXA PARENTERALS LIMITED | Not Listed | Yes | No | Not Applicable | AXA Parenterals Limited holds WHO-GMP certification. |
| AKRITI PHARMACEUTICALS PVT. LTD | Not Listed | Yes | No | Not Applicable | Akriti Pharmaceuticals Pvt. Ltd holds WHO-GMP certification. |
TransData Nexus reviewed the regulatory standing of 5 leading Ipratropium exporters from India. 2 hold US FDA facility approvals, 5 maintain WHO-GMP certification, and 2 are EU GMP compliant. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Ipratropium sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as India's "Bulk Drug Capital," is a pivotal center for active pharmaceutical ingredient (API) manufacturing. The city's Genome Valley hosts numerous R&D and biologics firms, while industrial areas like Bollaram and Pashamylaram are home to API and intermediate manufacturers. The ongoing development of Hyderabad Pharma City aims to integrate APIs, formulations, and support services within a unified cluster, enhancing production efficiency and scalability.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its robust pharmaceutical formulations industry. Ahmedabad, housing companies like Cadila Pharmaceuticals, focuses on producing a wide range of pharmaceutical products, including generic drugs and active pharmaceutical intermediates. Vadodara complements this with its manufacturing capabilities, contributing significantly to the region's pharmaceutical output.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a critical export gateway for India's pharmaceutical products. Mumbai, the headquarters of major companies like Sun Pharmaceutical Industries Limited and Cipla Limited, facilitates global distribution through its well-established infrastructure and proximity to major ports. Thane and Raigad districts support this with manufacturing facilities and R&D centers, enhancing the region's export capabilities.
4Baddi-Nalagarh — Tax Incentive Zone
The Baddi-Nalagarh region in Himachal Pradesh has emerged as a significant pharmaceutical manufacturing hub, initially attracting companies through tax incentives. Baddi, in particular, is recognized as Asia's largest pharmaceutical hub, hosting numerous manufacturing plants. Despite the expiration of initial tax holidays, the region continues to thrive due to its established infrastructure and skilled workforce.
5Sourcing Recommendations
- Diversify Supplier Base: While CIPLA LIMITED dominates Ipratropium exports (84.7%), consider engaging with other suppliers like AHLCON PARENTERALS (INDIA) LIMITED and SUN PHARMACEUTICAL INDUSTRIES LIMITED to mitigate supply chain risks.
- Leverage Regional Specializations: Utilize Hyderabad for API sourcing, Ahmedabad-Vadodara for formulations, and Mumbai-Thane-Raigad for export logistics to optimize the supply chain.
- Monitor Regulatory Compliance: Ensure all suppliers adhere to standards set by regulatory bodies such as the CDSCO and DGFT to maintain product quality and compliance.
- Assess Infrastructure and Logistics: Evaluate the logistical capabilities of regions like Baddi-Nalagarh, considering factors such as transportation and proximity to markets, to ensure efficient distribution.
By strategically engaging with these pharmaceutical clusters and suppliers, companies can enhance their supply chain resilience and capitalize on India's diverse manufacturing capabilities.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Ipratropium exporters from India
CIPLA LIMITED — Cipla acquires Ivia Beaute's personal care brands for ₹130 crore
In April 2024, Cipla Limited acquired the distribution and marketing business of Ivia Beaute Pvt Ltd for ₹130 crore, with an additional ₹110 crore contingent on milestones. This acquisition aims to expand Cipla's consumer health portfolio into personal care products. IMPACT: This strategic move is expected to diversify Cipla's revenue streams, potentially enhancing its financial stability and supporting sustained Ipratropium export levels.
Impact: This strategic move is expected to diversify Cipla's revenue streams, potentially enhancing its financial stability and supporting sustained Ipratropium export levels.
SUN PHARMACEUTICAL INDUSTRIES LIMITED — Sun Pharma acquires Concert Pharmaceuticals for $576 million
In March 2023, Sun Pharmaceutical Industries Limited completed the acquisition of Concert Pharmaceuticals, Inc., a U.S.-based biotechnology company, for $576 million. This acquisition is intended to bolster Sun Pharma's dermatology portfolio. IMPACT: While primarily enhancing Sun Pharma's dermatology offerings, the acquisition may lead to increased financial resources, indirectly supporting the company's Ipratropium export capabilities.
Impact: While primarily enhancing Sun Pharma's dermatology offerings, the acquisition may lead to increased financial resources, indirectly supporting the company's Ipratropium export capabilities.
SUN PHARMACEUTICAL INDUSTRIES LIMITED — Sun Pharma merges with Taro Pharmaceuticals in $347.73 million deal
In January 2024, Sun Pharma entered into a definitive merger agreement to acquire the remaining stake in Taro Pharmaceuticals for $347.73 million, consolidating its position in the generic pharmaceutical market. IMPACT: This merger is expected to strengthen Sun Pharma's market presence and financial position, potentially enhancing its capacity for Ipratropium exports.
Impact: This merger is expected to strengthen Sun Pharma's market presence and financial position, potentially enhancing its capacity for Ipratropium exports.
Common Questions — Ipratropium Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which ipratropium supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, CIPLA LIMITED leads with 402 recorded shipments worth $48.3M. AHLCON PARENTERALS (INDIA) LIMITED (53 shipments) and SUN PHARMACEUTICAL INDUSTRIES LIMITED (153 shipments) are also established high-volume exporters.
Q How many ipratropium manufacturers are there in India?
India has 173 active ipratropium exporters with a combined export market of $57.1M across 2,297 shipments to 81 countries. The top 5 suppliers hold 95.0% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for ipratropium from India?
Average FOB unit price: $9.01 per unit, ranging from $0.01 to $11607.35. Average shipment value: $24.8K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 173 verified Indian exporters of Ipratropium ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 2,297 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 81 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
2,297 Verified Shipments
173 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists